Giant cell arteritis: high dose steroids were not clearly better than low dose.
|
|
|
Clinical bottom line (level 1b-)
-
Patients with giant cell arteritis who were given low dose steroids, had no clear difference in treatment failure than those given high dose.
-
Patients with polymyalgia rheumatica who were given low dose steroids were more likely to have treatment failure than those given high dose
(NNT =
2
at
unknown)
.
-
In patients with either GCA or PMR, high dose steroids decreased treatment failure
(NNT =
3
at
unknown)
.
|
|
Kyle and Hazleman:
Annals of the Rheumatic Diseases
1989;
48:
658-661
|
Expires
November 2001
|
The study
?blinded ?concealed randomised
trial
?with
intention-to-treat
Setting: general hospital, UK
74 patients
(aged
?,
?%
male)
active untreated polymyalgia rheumatica (PMR)(n=39) or giant cell arteritis (GCA)(n=35)
Control Group: (n = 35, 35 analysed):
low dose steroids: PMR 10 mg/ day; GCA 20 mg/day. 20 patients with PMR; 15 with GCA
Experimental Group: (n = 39, 39 analysed):
high dose steroids: PMR 15-20 mg/ day; GCA 40 mg/day. 19 patients with PMR; 20 with GCA
If the disease process did not appear to be controlled or if new symptoms developed the prednisolone dose was altered to achieve adequate control.
100% followed for
?
Outcome notes:
-
treatment failure
: increase from the planned prednisolone dose or inability to reduce the prednisolone dose as planned
The evidence
patients with GCA
| Outcome |
Time to outcome |
CER | EER | RRR (95% CI) | ARR (95% CI) | NNT (95% CI) |
| treatment failure
|
weeks |
6 (40.0%) |
4 (20.0%) |
50% (-46% to
83%) |
20.0% (-10.4% to
50.4%) |
5
(NNT = 2 to infinity;
NNH =
10
to infinity)
|
patients with PMR
| Outcome |
Time to outcome |
CER | EER | RRR (95% CI) | ARR (95% CI) | NNT (95% CI) |
| treatment failure
|
unknown |
13 (65.0%) |
2 (10.5%) |
84% (38% to
96%) |
54.5% (29.4% to
79.5%) |
2
(1 to
3)
|
patients with GCA or PMR
| Outcome |
Time to outcome |
CER | EER | RRR (95% CI) | ARR (95% CI) | NNT (95% CI) |
| treatment failure
|
unknown |
19 (54.3%) |
6 (15.4%) |
72% (37% to
87%) |
38.9% (18.9% to
58.9%) |
3
(2 to
5)
|
Citation
-
Kyle
V,
and
Hazleman
BL:
Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.
Annals of the Rheumatic Diseases
1989;
48:
658-661
Contributor: Clare Wotton and Bob Phillips,
November 2000
Reviewer:
Clinical Question.
| Patient |
GCA or PMR |
| Intervention or Exposure |
high dose steroids |
| Comparison |
low dose steroids |
| Outcome |
requiring increased dose |
|
|